[HTML][HTML] Safety and survival with GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic …
DT Le, A Wang-Gillam, V Picozzi… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Journal of clinical Oncology, 2015•ncbi.nlm.nih.gov
Purpose GVAX pancreas, granulocyte-macrophage colony-stimulating factor–secreting
allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including
mesothelin. GVAX is administered with low-dose cyclophosphamide (Cy) to inhibit
regulatory T cells. CRS-207, live-attenuated Listeria monocytogenes–expressing
mesothelin, induces innate and adaptive immunity. On the basis of preclinical synergy, we
tested prime/boost vaccination with GVAX and CRS-207 in pancreatic adenocarcinoma.
allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including
mesothelin. GVAX is administered with low-dose cyclophosphamide (Cy) to inhibit
regulatory T cells. CRS-207, live-attenuated Listeria monocytogenes–expressing
mesothelin, induces innate and adaptive immunity. On the basis of preclinical synergy, we
tested prime/boost vaccination with GVAX and CRS-207 in pancreatic adenocarcinoma.
Abstract
Purpose
GVAX pancreas, granulocyte-macrophage colony-stimulating factor–secreting allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin. GVAX is administered with low-dose cyclophosphamide (Cy) to inhibit regulatory T cells. CRS-207, live-attenuated Listeria monocytogenes–expressing mesothelin, induces innate and adaptive immunity. On the basis of preclinical synergy, we tested prime/boost vaccination with GVAX and CRS-207 in pancreatic adenocarcinoma.
ncbi.nlm.nih.gov